Kintera Leadership
| Name Company Title Address Telephone Fax |
Harry
Gruber, M.D. Kintera, Inc. Chief Executive Officer 9605 Scranton Road Suite 240 San Diego, CA 92121 858-795-3038 858-795-3010 |
-
BA, University of Pennsylvania - MD, University of Pennsylvania - Internal Medicine, Rheumatology and Biochemical - Genetics, University of California |
|
|
EXPERIENCE
|
|
| Kintera, Inc. San Diego, CA |
1999 – Present |
CEO, Co-Founder and Chairman Dr. Harry Gruber established Kintera, Inc. as the leading Internet marketing services provider offering nonprofit organizations advanced web-based solutions to help raise awareness and funds. Kintera’s services, highlighted by its proprietary “Friends Asking Friends™” technology, leverage the power of the Internet to enrich user experiences when interacting with nonprofit organizations. The company’s end-to-end Internet solutions meld with traditional fundraising to enhance donor recruitment, cultivation and stewardship programs. |
|
| INTERVU, Inc. San Diego, CA |
1995-2000 |
CEO, CFO, President, Founder and Chairman INTERVU, Inc. was founded by Dr. Gruber in 1996 as an Internet video and audio delivery company, with the goal of entertaining and communicating via the Web. He co-invented and commercialized a distributed network system for delivering video and audio content over the Internet from the electronically closest delivery location. INTERVU attracted strategic investments from Microsoft (NASDAQ: MSFT), NBC (NYSE: GE) and Time-Warner (NYSE: AOL)/CNN, and formed major alliances with AT&T (NYSE: T), MCI WorldCom (NASDAQ: WCOM) and Global Crossing (NYSE: GX). Akamai Technologies, Inc acquired INTERVU for $2.8 billion. |
|
| Gensia, Inc. San Diego, CA |
1986-1995 |
Chief Scientific Officer, Vice President Research and Founder Dr. Gruber left a research position with the University of California, San Diego in 1986 to form his first entrepreneurial venture, Gensia, a biotech research firm that was the basis for two additional businesses: Aramed and Viagene, the world’s first gene therapy company. Gensia completed initial public offering in 1990, and achieved a public market capitalization of $1.7 billion before the firm was subsequently acquired. |
|
| Viagene, Inc. San Diego, CA |
1987-1994 |
Founder Viagene was a pioneer in the study of gene therapy. The world’s first gene therapy company went public in 1993 with a market cap of $100 million. Soon, Viagene was showing enough promise to become attractive to a much larger competitor, Chiron, which bought the company in 1994 for $150 million. |
|
| Aramed, Inc. San Diego, CA |
1991-1995 |
Founder Another spin-off of Gensia, Aramed was a drug discovery company focused on the central nervous system. The biotech firm achieved a public market capitalization of approximately $600 million, and was subsequently bought back by Gensia. |
|
| University of California,
San Diego School of Medicine San Diego, CA |
1977-1986 |
Researcher, Professor Beginning his professional career as a medical doctor, Dr. Gruber joined the faculty of UCSD School of Medicine as a geneticist and rheumatologist, and also as a researcher. After nine years, he left to found his first entrepreneurial venture, Gensia. |
|
Affiliations:
|
|